![[LSUK] Life-Sciences-UK.com - The UK Life Sciences Web Portal](/images/basics/lsuk-life-sciences-uk-portal-logo.svg){kind=logo}
Advertisement
Persons > All
Please find below persons from Ireland & the United Kingdom (GB) or related to organisations from these countries.Total search results: 4952 | Ordered by Organisation (Group) (ascending)
1 2 3 ... 31 32 33 ... 48 49 50 
  Person |
Position |
 Organisation (Group) |
Region |
|---|---|---|---|
| Sturmhoefel, Knut (Novartis 201511 Head BD&L Ophthalmology + Respiratory) | Business Development Manager / Strategy Manager | Novartis (Group) | Northwestern Switzerland (region) |
| Yeadon, Mike (Ziarco Pharma 201211– CEO + founder before Pfizer Research UK) | Chief Executive Officer (CEO) | Novartis (Group) | South East England (region) |
| D’Hooge, François (Novasep 201609– Bioconjugation Unit Manager before Spirogen/AstraZeneca + Glythera) | President/Director/Head Business Group/Unit/Division | Novasep (Group) | Grand Est (Great East) (region) |
| Nicoud, Roger-Marc (Novasep 201210–201302 Non-executive Chairman before CEO + founder) | Chief Executive Officer (CEO) | Novasep (Group) | Grand Est (Great East) (region) |
| Spagnol, Michel (Novasep 201306– CEO before Shasun + Rhodia) | Chief Executive Officer (CEO) | Novasep (Group) | Grand Est (Great East) (region) |
| Daniels, Rob (NovaThera 200507 Head BusDev + Licensing) | Business Development Manager / Strategy Manager | NovaThera Ltd. | United Kingdom (state/region unspecified) |
| Roberts, Gareth (NovaThera 200507 CEO) | Chief Executive Officer (CEO) | NovaThera Ltd. | United Kingdom (state/region unspecified) |
| Björgólfsson, Thor (Novator Partners 2004– Chairman + Founder) | Board member, executive | Novator Partners (Group) | Greater London (region) |
| Ragnarsson, Birgir Már (Novator Partners 202205 Partner) | Partner (venture partner) | Novator Partners (Group) | Greater London (region) |
| Sveinsson, Andri (Novator Partners 202010 Managing Partner) | Managing Partner | Novator Partners (Group) | Greater London (region) |
| Barbut, Jack (Novimmune 201012–201512 CEO until 12/15) | Chief Executive Officer (CEO) | Novimmune S.A. | Région Lémanique (region) |
| Mills, Adrian (Novimmune 201409– CBO before GSK since 2000) | Chief Business Officer (CBO) | Novimmune S.A. | Région Lémanique (region) |
| Edwards, Martin (Novo AS 200902 Senior Partner + Symphogen 200902 Board Chairman) | Partner (venture partner) | Novo Group (Group) | Hovedstaden |
| Ghenchev, Robert (Novo Group 201905 Director at Novo Holdings) | President/Director/Head Business Group/Unit/Division | Novo Group (Group) | Hovedstaden |
| Graugaard Døssing, Morten (Novo Group 201802 Prinicpal at Novo Seeds) | Principal (venture capital) | Novo Group (Group) | Hovedstaden |
| Helfgott, Ludovic (Novo Nordisk 202209 EVP + Head of Rare Disease formerly AstraZeneca 201506 President Spain) | President/Director/Head of Research Organisation/Unit | Novo Group (Group) | Denmark_o |
| Mahony, Daniel (Dan) (Novo Group 202401– Senior Partner Novo Growth Investments + BIA before Trellus + Evotec) | n. a. | Novo Group (Group) | Hovedstaden |
| Petrycer Hansen, Camilla (Novo Group 202012 Senior Associate at Novo Seeds) | venture capital | Novo Group (Group) | Hovedstaden |
| Schindler, Marcus (Novo Nordisk 201801– before AstraZeneca) | President/Director/Head Business Group/Unit/Division | Novo Group (Group) | Denmark_o |
| Siddiqi, Naveed (Novo Ventures 201912– Partner before 201312– Partner at EdRIP BioDiscovery Funds + Phase4 Ventures) | Partner (venture partner) | Novo Group (Group) | Hovedstaden |
| Cafferkey, John (Novogene 202312 Marketing Director at Novogene Europe) | Sales Manager / Marketing Manager | Novogene (Group) | United Kingdom (state/region unspecified) |
| Zhou, Tingting (Novogene 202312 VP of Novogene Europe) | President/Director/Head Business Group/Unit/Division | Novogene (Group) | United Kingdom (state/region unspecified) |
| Pearson, Dermot (Novo Group 201310 Marketing Director at Novozymes Biopharma) | Sales Manager / Marketing Manager | Novozymes (Group) | Denmark_o |
| Griffith, Hugh S. (NuCana Biomed 2008 CEO + co-founder before Bioenvision) | Chief Executive Officer (CEO) | NuCana plc (Nasdaq: NCNA) | Scotland |
| Kay, Andrew (NuCana 202012– Board Chairman also at Boards of NeRRe Tx + Blueberry Tx former CEO of Algeta) | Board member, non-executive | NuCana plc (Nasdaq: NCNA) | Scotland |
| Wood, Christopher B. (Chris) (NuCana Biomed 2008– Executive Chair + Co-founder before Bioenvision 1999–2007 CEO) | Chief Executive Officer (CEO) | NuCana plc (Nasdaq: NCNA) | Scotland |
| Lopez, Mary F. (Nuclea Biotechnologies 201502– COO before Thermo Fisher BRIMS + PerkinElmer + Proteome Systems) | Chief Operating Officer (COO) | Nuclea Biotechnologies Inc. | Massachusetts (federal state) |
| Clark, Nigel (Nucleome Therapeutics 202210 CBO before Kymab + Syntaxin + Vernalis + Ribotargets) | Business Development Manager / Strategy Manager | Nucleome Therapeutics Ltd. | South East England (region) |
| Jeziorska, Danuta M. (Nucleome Therapeutics 202210 CEO + Co-Founder) | Chief Executive Officer (CEO) | Nucleome Therapeutics Ltd. | South East England (region) |
| Bertelsen, Jospeh (Joe) (Nuclera 202403– Chief Commercial Officer before Institute for Protein Innovation + Diagenode) | Chief Commercial Officer (CCO) | Nuclera (Group) | East of England (region) |
| Chen, Michael (Nuclera 202202 CEO + Co-Founder) | Chief Executive Officer (CEO) | Nuclera (Group) | East of England (region) |
| Vasella, Daniel (Novartis CEO 199612–201001 after 1/10 continues as Chairman) | Board member, non-executive | Numab (Group) | Zürich (region) |
| Vicary, James (NuNano 201711 Managing Director + Co-Founder) | Managing Director | NuNano (GB) | South West England (region) |
| Lucier, Gregory T. (NuVasive 201505– CEO before CEO of Life Technologies + Invitrogen 2003–2014) | Chief Executive Officer (CEO) | NuVasive (Group) | California (federal state) |
| Bentsur, Ron (Nuvectis Pharma 202110 CEO + Co-Founder formerly at UroGen Pharma + Kery Biopharmaceuticals) | Chief Executive Officer (CEO) | Nuvectis Pharma Inc. | New Jersey (federal state) |
| Siddeek, Mohamed (Sid) (Nvidia 202403 Corporate VP + Head of NVentures) | President/Director/Head Business Group/Unit/Division | NVentures (Nvidia) | |
| Powell, Kimberly (Nvidia 202010 VP of Healthcare) | President/Director/Head Business Group/Unit/Division | Nvidia (Group) | California (federal state) |
| Suk, John (Nycomed Canada –200801– President + CEO) | Chief Executive Officer (CEO) | Nycomed (Group) | Canada_o |
| Shah, Sunil (o2h Discovery Ltd 201806 CEO) | Chief Executive Officer (CEO) | o2h (Group) | East of England (region) |
| Matthews, Andy (O2PR 2002– Founder) | public relations / investor relations | O2PR – Andy Matthews | East of England (region) |
| Schad, Martina (OakLabs GmbH 201103–Managing Director + founder before imaGenes Assoc Director Microarray Services) | Managing Director | OakLabs GmbH | Brandenburg (federal state) |
| Cook, Rod (OBN 201506 Non-executive Director) | Board member, non-executive | OBN (UK) Ltd. | South East England (region) |
| Harris, John G. (OBN 201604 CEO) | Cluster Manager | OBN (UK) Ltd. | South East England (region) |
| Hart, Julie (OBN 201409– Assoc Director of Networking before BBI Solutions/Alere + AbD Serotec) | Cluster Manager | OBN (UK) Ltd. | South East England (region) |
| Hooper, Mark (OBN 201701– Head Business Development before Conversis Medical + Pharmaterials + Johnson Matthey) | Business Development Manager / Strategy Manager | OBN (UK) Ltd. | South East England (region) |
| Laskow-Pooley, David (OBN 201506 Chairman) | Board member | OBN (UK) Ltd. | South East England (region) |
| Pratley, Lee (OBN 201611 Assoc Director Purchasing + Membership Development) | Cluster Manager | OBN (UK) Ltd. | South East England (region) |
| Rose, Stuart (OBN 202401 CEO formerly Oxford Immunotec 200501– Global Marketing Director before pharmaSMART Consulting) | Chief Executive Officer (CEO) | OBN (UK) Ltd. | South East England (region) |
| Sommerville, Ross (OBN 201506– Interim CEO) | Chief Executive Officer (CEO) | OBN (UK) Ltd. | South East England (region) |
| Taylor, Amanda (OBN 201211 Senior Business Development Manager) | Cluster Manager | OBN (UK) Ltd. | South East England (region) |
| Walker, Sarah (OBN 201905 Senior Events Manager) | Event Manager / Conference Manager | OBN (UK) Ltd. | South East England (region) |
| Waterman, Sally (OBN 2014–201812 Board Chairman) | Board member, non-executive | OBN (UK) Ltd. | South East England (region) |
| Briers, Yves (Obulytix 202401 CEO + Co-Founder & Professor at Ghent Univ) | Chief Executive Officer (CEO) | Obulytix (BE) | Flanders (Flemish region) |
| O’Meara, Jack (Ochre Bio 202106 CEO + Co-Founder) | Chief Executive Officer (CEO) | Ochre Bio Ltd. | South East England (region) |
| Choudry, Uzma (Octopus Ventures 202107 Early-state Investor) | Investment Manager | Octopus Ventures (GB) | Greater London (region) |
| Gunterberg, Jacob (HealthCap 202011 Partner) | Partner (venture partner) | Odlander Fredrikson (Group) | Stockholm (region) |
| Odlander, Björn (HealthCap 200406 Managing Director + Jerini Board Member) | Managing Director | Odlander Fredrikson (Group) | Stockholm (region) |
| Glick, Gary D. (Odyssey Therapeutics 202112 CEO + Co-Founder before Scorpion Therapeutics + IFM Therapeutics) | Chief Executive Officer (CEO) | Odyssey Therapeutics (Group) | Massachusetts (federal state) |
| Brenner, Sydney | n. a. | Okinawa Institute of Science and Technology (OIST) | Kyushu (region) |
| Bouarfa, Loubna (Okra Technologies 201911 CEO + Founder) | Chief Executive Officer (CEO) | Okra Technologies Ltd. | East of England (region) |
| Al-Khattawi, Ali (Mesox 2021– CEO + Co-Founder) | Chief Executive Officer (CEO) | Olgram SAS | France (region/state unspecified) |
| Rocheteau, Pierre (Olgram 202401 CEO + Co-Founder) | Chief Executive Officer (CEO) | Olgram SAS | France (region/state unspecified) |
| Pollack, Leonhard (Olink Proteomics 201605– Scientific Sales Specialist before Schauenburg/Markes + Nonlinear Dynamics) | Sales Manager / Marketing Manager | Olink (Group) | Uppsala (region) |
| Ahrent, Esther (Olympus Life + Material Science Europa GmbH 200704 Section Manager Marketing Comm Microscopy) | n. a. | Olympus (Group) | Hamburg (federal state) |
| Breasley, Kerri (Olympus 200808 Commercial Marketing Manager Clinical Chemistry) | Sales Manager / Marketing Manager | Olympus (Group) | Kanto (region) |
| Kikukawa, Tsuyochi (Olympus 200607 President Oympus Corp) | President/Director/Head Business Group/Unit/Division | Olympus (Group) | Kanto (region) |
| Brown, Giles (OMass 201811– VP Medicinal Chemistry before Heptares Therapeutics + Cambridge Biotechnology + Evotec OAI) | Researcher (industry) | OMass Therapeutics Ltd. | South East England (region) |
| Deegan, Rosamond (Ros) (OMass Therapeutics 201905– CEO before Bicycle Therapeutics + Trevena + GSK) | Chief Executive Officer (CEO) | OMass Therapeutics Ltd. | South East England (region) |
| Hopper, Jonathan (OMass 201811 CEO + Co-Founder) | Chief Executive Officer (CEO) | OMass Therapeutics Ltd. | South East England (region) |
| Jazayeri, Ali (OMass 201811– CSO before Heptares Therapeutics + Clare Hall Laboratories + Kudos Pharmaceuticals) | Chief Scientific Officer (CSO) / Chief Development Officer (CDO) | OMass Therapeutics Ltd. | South East England (region) |
| Loke, Hsin (OMass 201811– VP Head of Finance + Strategy before 16 years at GSK) | Chief Financial Officer (CFO) | OMass Therapeutics Ltd. | South East England (region) |
| Grewal, Jag (Omega Diagnostics 201311 Group Sales + Marketing Director) | Sales Manager / Marketing Manager | Omega Diagnostics (Group) | Greater London (region) |
| Harbinson, Kieron (Omega Diagnostics 201311 Group Finance Director) | Chief Financial Officer (CFO) | Omega Diagnostics (Group) | Greater London (region) |
| King, Colin (Omega Diagnostics 201508– COO before Managing Director at Axis-Shield Diagnostics) | Chief Operating Officer (COO) | Omega Diagnostics (Group) | Greater London (region) |
| Shepherd, Andrew (Omega Diagnostics 201311 Chief Executive) | Chief Executive Officer (CEO) | Omega Diagnostics (Group) | Greater London (region) |
| Doig, Michelle (Omega Funds 202107 Partner + Head of Corporate Development) | Partner (venture partner) | Omega Funds (Group) | Massachusetts (federal state) |
| Nessi, Claudio (Omega Funds 202211 before NeoMed Management 201309) | Investment Manager | Omega Funds (Group) | Massachusetts (federal state) |
| Fischer, Robert (Omeicos Therapeutics GmbH 201312 Managing Director (CSO)) | Managing Director | Omeicos (Group) | Berlin (federal state) |
| Jones, Andy (Omic Analytics 201703 + Prof) | Managing Director | Omic Analytics Ltd. | Yorkshire and the Humber (region) |
| Bérces, Attila (Omixon 200411– CEO + Founder) | Chief Executive Officer (CEO) | Omixon Biocomputing Kft. | Central Hungary (region) |
| Hague, Tim (Omixon 201311 CEO) | Chief Executive Officer (CEO) | Omixon Biocomputing Kft. | Central Hungary (region) |
| Russell, Stephen J. (Omnis Pharmaceuticals 201501 CEO) | Chief Executive Officer (CEO) | Omnis Pharmaceuticals (US) | Minnesota (federal state) |
| Haft, Nick (OMX Ventures 202207 Managing Director) | Managing Director | OMX Ventures | |
| Courtieu, Bernard (IntegraGen 201203 CEO) | Chief Executive Officer (CEO) | OncoDNA (Group) | Île-de-France (region) |
| Riot Lamotte, Laurence (IntegraGen 201110– CFO before Aureus Pharma 200411–20010 CFO) | Chief Financial Officer (CFO) | OncoDNA (Group) | Île-de-France (region) |
| Eitner, Casey (Expression Pathology 200806 CEO) | Chief Executive Officer (CEO) | OncoPlex Diagnostics (OncoPlexDx) | Maryland (federal state) |
| Jones, Tony (One Nucleus 201708– CEO before Director of Business Development) | Chief Executive Officer (CEO) | One Nucleus | East of England (region) |
| Takino, Toichi (Ono Pharmaceutical 202201 Executive Director Discovery + Research) | President/Director/Head Business Group/Unit/Division | Ono Pharmaceutical (Group) | Kinki (region) |
| Dixon, Graham (Onxeo 2015– CSO before Sensorion + Addex + Galapagos + Entomed + F2G + AstraZeneca) | Chief Scientific Officer (CSO) / Chief Development Officer (CDO) | Onxeo (Group) | Île-de-France (region) |
| Leroy, Valerie (Onxeo 201612– Director IR + Corp Communications before Genticel + Carmat + Edwards Lifesciences) | Public Relations Manager / Investor Relations Manager | Onxeo (Group) | Île-de-France (region) |
| Winterhalter, Karen (Onyx Health PR 201808 Managing Director + Founder) | Public Relations Manager / Investor Relations Manager | Onyx Health Ltd. (Onyx Health PR) | North East England (region) |
| Gibson, Luke (Open Pharma Research 201907 Managing Director + Co-Founder before Euromoney + Informa) | Managing Director | Open Pharma Research Ltd. | Greater London (region) |
| Marshall, Kirianne (Open Pharma Research 201907 Managing Director + Co-Founder before IIR + IBC) | Managing Director | Open Pharma Research Ltd. | Greater London (region) |
| Tharia, Zahid (Open Pharma Research 201907 Managing Director + Co-Founder before Health Network + Informa) | Managing Director | Open Pharma Research Ltd. | Greater London (region) |
| Morgan, Geraint (Agilent 201105 Centre Director Agilent Centre of Excellence in Comprehensive Chromatography UK) | Laboratory Manager (industry) | Open University, The | South East England (region) |
| Grandy, Jeffrey (OpenEye Scientific 202005 Chief Commercial Officer) | Chief Commercial Officer (CCO) | OpenEye Scientific (Group) | New Mexico (federal sate) |
| Nicholls, Anthony (OpenEye Scientific 202005 CEO + Founder) | Chief Executive Officer (CEO) | OpenEye Scientific (Group) | New Mexico (federal sate) |
| Lim, Riwat (Curetis 2017Q3– Managing Director of Curetis UK Ltd + Commercial Director EMEA before Qiagen) | Managing Director | OpGen (Group) | United Kingdom (state/region unspecified) |
| O’Hara, Stephen (OptiBiotix 201703 CEO) | Chief Executive Officer (CEO) | OptiBiotix Health (Group) | Yorkshire and the Humber (region) |
| Devlin, Clare (Optibrium 201901– Financial Director before Scintacor + Addviso + Genestack) | Chief Financial Officer (CFO) | Optibrium (Group) | East of England (region) |
1 2 3 ... 31 32 33 ... 48 49 50
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
